GPCR-tailored pharmacophore pattern recognition of small molecular ligands

Journal of Chemical Information and Computer Sciences

Volumn 44, Issue 3, 2004, Pages 1137-1147

  Von Korff, Modest ^b   Steger, Matthias ^a,b  

^a Axovan Ltd   (Switzerland)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; COMPUTATIONAL METHODS; DATABASE SYSTEMS; DRUG PRODUCTS; OPTIMIZATION; PATTERN RECOGNITION; PHYSICAL CHEMISTRY; PROTEINS; SELF ORGANIZING MAPS;

G-PROTEIN COUPLED RECEPTORS (GPCR); HIGH-THROUGHPUT SCRENING (HTS); MOLECULAR LIGANDS; TRANSMEMBRANE HELICES;

MOLECULAR DYNAMICS;

G PROTEIN COUPLED RECEPTOR; LIGAND;

ARTICLE; AUTOMATED PATTERN RECOGNITION; CHEMISTRY;

LIGANDS; PATTERN RECOGNITION, AUTOMATED; RECEPTORS, G-PROTEIN-COUPLED;

EID: 2942715359     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci0303013     Document Type: Article

References (81)

1. Wise, A.; Gearing, K.; Rees, S. Target validation of G-protein coupled receptors. Drug Discovery Today 2002, 7(4), 235-246.
2. (a) Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C.; Zody, M. C.; Balwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860-921.
3. (b) Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W.; Mural, R. J.; Sutton, G. G.; Smith, H. O.; Yandell, M.; Evans, C. A.; Holt, R. A. The sequence of the human genome. Science 2001, 291, 1304-1351.
4. Chalmers, D. T.; Behan, D. P. The use of constitutively active GPCRs in drug discovery and functional genomics. Nature Rev. Drug Discovery 2002, 1, 599-608.
5. Bockaert, J. G protein-coupled receptors. Encyclopedia Life Sci. 2001, 1-9.
6. Kawasawa, Y.; McKenzie, M. L.; Hill, D. P.; Bono, H.; Yanagisawa, M. G protein-coupled receptor genes in the Fantom2 database, Genome Res. 2003, 13, 1466-1477.
7. (a) Downs, G. M.; Barnard, J. M. Clustering Methods and their uses in Computational Chemistry. Rev. Comput. Chem. 2002, 18, 1-40.
8. (b) Pearlman, R. S.; Smith, K. M. Metric validation and the receptor-relevant subspace concept. J. Chem. Inf. Comput Sci. 1999, 39, 28-35.
9. (a) Martin, Y. C.; Kofron, J. L.; Traphagen, L. M. Do structurally similar molecules have similar biological activity?. J. Med. Chem. 2002, 45, 4350-4358.
10. (b) Oprea, T. I.; Zamora, I.; Ungell, A.-L. Pharmacokinetically based mapping device for chemical space navigation. J. Comb. Chem. 2002, 4, 258-266.
11. (c) Clark, D. E.; Pickett, S. D. Computational methods for the prediction of 'drug-likeness'. Drug Discovery Today 2000, 5(2), 49-58.
12. (d) Kubinyi, H. Molekulare Aehnlichkeit. Pharmazie in unserer Zeit 1998, 27(3), 92-106 and 158-172.
13. (e) Sadowski, J.; Kubinyi, H. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 1998, 41, 3325-3329.
14. Manallack, B. G.; Pitt, W. R.; Gancia, E.; Montana, J. G.; Ford, M. G.; Livingstone, D. J.; Whitley, D. C. Selecting screening candidates for kinase and G protein-coupled receptor targets using neural networks. J. Chem. Inf. Comput. Sci. 2002, 42, 1256-1262.
15. 2A) antagonists using self-organizing maps. J. Comb. Chem. 2003, 5, 233-237.
16. (b) Pascual, R.; Mateu, M.; Gasteiger, J.; Borrell, J. I.; Teixido, J. Design and analysis of combinatorial library of KEPT analogues: comparison of selection methodologies and inspection of the actually covered chemical space. J. Chem. Inf. Comput. Sci. 2003, 43, 199-207.
17. (c) Brunne, R. M.; Hessler, G.; Muegge, I. In Handbook of Combinatorial Chemistry; Nicolaou, K. C., Hanko, R., Hartwig, W., Eds.; Wiley-VCH: Weinheim, 2002; Vol. 1, Chapter 27, pp 761-783.
18. (d) Poulain, R.; Horvath, D.; Bonnet, B.; Eckhoff, C.; Chapelain, B.; Bodinier, M.-C.; Déprez, B. From hit to lead. Combining two complementary methods for focused library design. Application to m opiate ligands. J. Med, Chem. 2001, 44, 3378-3390.
19. (e) Andrews, K. M.; Cramer, R. D. Towards general methods of targeted library design: Topomer shape similarity searching with diverse structures as queries. J. Med. Chem. 2000, 43, 1723-1740.
20. (a) Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationship and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
21. (b) Palomer, A.; Cabré, F.; Pascual, J.; Campos, J.; Trujillo, M. A., Entrena, M. A. G.; Garcia, L.; Mauleon, D.; Espinosa, A. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J. Med. Chem. 2002, 45, 1402-1411.
22. (c) Fisher, L. S.; Güner, O. F.; Seeking novel leads through structure-based pharmacophore design. J. Braz. Chem. Soc. 2002, 13 (6), 777-787.
23. (d) Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. 'Scaffold-hopping' by topological pharmacophore search: A contribution to virtual screening. Angew. Chem., Int. Ed. 1999, 38 (19), 2894-2896.
24. (a) Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physicochemical property profiles of development and marketed oral drags. J. Med. Chem. 2003, 46, 1250-1256.
25. (b) Manallack, D. T.; Tehan, B. G.; Gancia, E.; Hudson, B. D.; Ford, M. G.; Livingstone, D. J.; Whitley, D. C.; Pitt, W. R. A consensus neural network-based technique for discriminating soluble and poorly soluble compounds. J. Chem. Inf. Comput. Sci. 2003, 43, 647-679.
26. (c) Härter, M. W.; Keldenich, J.; Schmitt, W. In Handbook of Combinatorial Chemistry; Nicolaou, K. C., Hanko, R., Hartwig, W., Eds.; Wiley-VCH: Weinheim, 2002; Vol. 1, Chapter 26, pp 743-759.
27. (d) Cronin, M. T. D. Computational methods for the prediction of drug toxicity. Curr. Opin. Drug Discovery Dev. 2000, 3(3), 292-297.
28. (a) Gobbi, A.; Lee, M.-L. DISE: Directed sphere exclusion. J. Chem. Inf. Comput. Sci. 2003, 43, 317-323.
29. (b) Godden, J. W.; Furr, J. R.; Bajorath, J. Recursive median partitioning for virtual screening of large databases. J. Chem. Inf. Comput. Sci. 2003, 43, 182-188.
30. (c) Godden, J. W.; Xue, L.; Bajorath, J. Classification of biologically active compounds by median partitioning. J. Chem. Inf. Comput. Sci. 2002, 42, 1263-1269.
31. (d) Schuffenhauer, A.; Floersheim, P.; Acklin, P.; Jacoby, E. Similarity metrics for ligands reflecting the similarity of the target proteins. J. Chem. Inf. Comput. Sci. 2003, 43, 391-405.
32. Anderson, J. C.; Baddeley, R. J.; Osorio, D.; Shashar, N.; Tyler, C. W.; Ramachandran, V. S.; Crook, A. C.; Hanlon, R. T. Modular organization of adaptive colouration in flounder and cuttlefish revealed by independent component analysis. Network: Comput. Neural Syst. 2003, 14, 321-333.
33. (a) Balakin, V. K.; Stanley, A. L.; Skorenko, A. V.; Tkachenko, S. E.; Ivashchenko, A. A.; Savchuk, N. P. Structure-based versus property-based approaches in the design of G-protein-coupled receptor-targeted libraries. J. Chem. Inf. Comput. Sci. 2003, 43, 1553-1562.
34. (b) Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 2002, 3, 928-944.
35. (c) Balakin, V. K.; Tkachenko, S. E.; Stanley, A. L.; Okun, I.; Ivash-chenko, A. A.; Savchuk, N. P. Property-based design of GPCR-targeted library. J. Chem. Inf. Comput. Sci. 2002, 42, 1332-1342.
36. (d) Jacoby, E. A novel chemogenomics knowledge-based ligand design strategy - application to G protein-coupled receptors. Quant. Struct.-Act. Relat. 2001, 20, 115-123.
37. Frye, S. V. Structure-activity relationship homology (SARAH): A conceptual framework for drug discovery in the genomic era. Chem. Biol. 2001, 6, R3-7.
38. Miller, M. A. Chemical database techniques in drug discovery. Nature Rev. Drug Discovery 2002, 1, 220-227.
39. MDL Drug Data Report, MDL ISIS/HOST software, MDL Information Systems, Inc.
40. Derwent World Drug Index, MDL ISIS/HOST software, Derwent Information Ltd.
41. Jacoby, E.; Schuffenhauer, A.; Floersheim, P. Chemogenomics knowledge-based strategies in drug discovery. Drug News Perspect 2003, 16(2), 93-102.
42. Prous Science, DailyDrugNews.com, www.prous.com/home_daily/ index.html
43. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors; Wiley-VCH: Weinheim, 2000.
44. (a) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubilty and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
45. (b) Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physico-chemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46, 1250-1256.
46. (c) Brüstle, M.; Beck, B.; Schindler, T.; King, W.; Mitchell, T.; Clark, T. Descriptors, physical properties and drug-likeness. J. Med. Chem. 2002, 45, 3345-3355.
47. (d) Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
48. (e) Walters, W. P.; Murcko, M. A. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 1999, 3, 384-387.
49. Böhm, H.-J.; Klebe, G. What can we learn from molecular recognition in protein ligand complexes for the design of new drugs? Angew. Chem., Int. Ed. 1996, 35, 2588-2614.
50. (a) Bernard, D.; Coop, A.; MacKerell, A. D. 2D Conformationally sampled pharmacophore: A ligand-based pharmacophore to differentiate δ opioid agonists from antagonists. J. Am. Chem. Soc. 2003, 125, 3101-3107.
51. (b) Singh, J.; Van Vlijmen, H.; Liao, A.; Lee, W.-C; Comebise, M.; Harris, M.; Shu, I.; Gill, A.; Cuervo, J. H.; Abraham, W. M.; Adams, S. P. Identification of potent and novel α.4β1 antagonists using in silico screening. J. Med. Chem. 2002, 45, 2988-2993.
52. 1 cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity and molecular modeling. J. Med. Chem. 2002, 45, 1748-1756.
53. (d) Debnath, A. K. Pharmacophore mapping of a series of 2,4,-Diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J. Med. Chem. 2002, 45,41-53.
54. (e) Poulain, R.; Horvath, D.; Bonnet, B.; Eckhoff, C.; Chapelain, B.; Bodinier, M.-C.; Déprez, B. From hit to lead. Analyzing structure-profile relationships. J. Med. Chem. 2001, 44, 3391-3401.
55. (t) Muegge, I.; Heald, S. L.; Brittelli, D. Simple selection criteria for drug-like chemical matter. Poulain, R.; Horvath, D.; Bonnet, B.; Eckhoff, C.; Chapelain, B.; Bodinier, M.-C.; Déprez, B. From hit to lead. Analyzing structure-profile relationships. J. Med. Chem. 2001, 44, 1841-1846.
56. (g) McGregor, M. J.; Muskal, S. M. Pharmacophore Fingerprinting. 2. Application to primary library design. J. Chem. Inf. Comput. Sci. 2000, 40, 117-125.
57. Teller, D. C.; Okada, T.; Behnke, C. A.; Palczewski, K.; Stenkamp, R. E. Advances in determination of a high-resolution three-dimensional structure of Rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001, 40(26), 7761-7772.
58. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Prot.: Struct., Funct. Genet. 2003, 50, 5-25.
59. (a) Carhart, R. E.; Smith, D. H.; Venkataraghavan, R. Atom pairs as molecular features in structure-activity studies: definition and applications. J. Chem. Inf. Comput. Sci. 1985, 25, 64-73.
60. (b) Baumann, K. An alignment-indipendent versatile structure descriptors for QSAR and QSPR based on the distribution of molecular features. J. Chem. Inf. Comput. Sci. 2002, 42, 26-35.
61. (a) Kearsley, S. K.; Sallamack, S.; Fluder, E. M.; Andose, J. D.; Morsley, R. T.; Sheridan, R. P. Chemical similarity using physichochemical property descriptors. J. Chem. Inf. Comput. Sci. 1996, 36, 118-127.
62. (b) Sheridan, P. R.; Miller, M. D. A method for visualizing recurrent topological substructures in sets of active molecules. J. Chem. Inf. Comput. Sci. 1998, 38, 915-924.
63. Zuccotto, F. Pharmacophore features distribution in different classes of compounds. J. Med. Chem. 2003, 46, 1542-1552.
64. Website: http://www.jchem.com/doc/user/GenerFP.html
65. Jollife, I. T. Principal Component Analysis; Springer: New York, 1986; Chapter 1, pp 1-5.
66. Duda, R. O.; Hart, P. E.; Stork, D. G. Pattern Classification; Wiley: New York, 2000.
67. Gordon, A. Classification; Chapman and Hall: London, 1981; Chapter 3, pp 33-53.
68. Sammon, J. W. A nonlinear mapping for data analysis. IEEE Trans. Comput. 1969, C(18), 401-409.
69. Kohonen, T. Self-Organizing Maps; Springer: New York, 2001.
70. Ye, J. On measuring and correcting the effects of data mining and model selection. J. Am. Stat. Assoc. 1998, 93, 401-409.
71. Dasarathy, B. V. Nearest Neighbor (NN) Norms: NN Pattern Classication Techniques; IEEE Computer Society Press: Los Alamitos, CA, 1990.
72. Harrison, P. W.; Barlin, G. B.; Davies, L. P.; Ireland, S. J.; Matyus, P.; Wong, M. G. Syntheses, pharmacological evaluation and molecular modeling of substituted 6-alkoxyimidazo[1,2-b]pyridazines as new ligands for the benzodiazepine receptor. Eur. J. Med. Chem. 1996, 31, 651-662.
73. Website: http://www.chemaxon.com/jchem/doc/user/fingerprint.html
74. Niiyama, K.; Takahashi, H.; Nagase, T.; Kojima, H.; Amano, Y.; Katsuki, K.; Yamakawa, T.; Ozaki, S.; Ihara, M.; Yano, M.; Fukuroda, T.; Nishikibe, M.; Ishikawa, K. Structure-activity relationship of 2-substituted 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids as a novel class of endothelin receptor antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 3041-3045.
75. Rawson, D. J.; Dack, K. N.; Dickinson, R. P.; James, K. The design and synthesis of a novel series of indole derived selective ETA antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 125-128.
76. Roux, S.; Breu, V.; Ertel, S. I.; Clozel, M. Endothelin antagonism with bosentan: a review of potential applications. J. Mol. Med. 1999, 77, 364-376.
77. Banks, B. J.; Chubb, N. A. L.; Eshelby, J. J.; Schulz, D. J. Pyrazoles and their use as endothelin antagonists; EP1072597; Pfizer Ltd. (GB), Pfizer (US), 2001.
78. Ishizuka, N.; Ken-ichi, M.; Katsunori, S.; Masafumi, F.; Shin-ichi, M.; Yamamori, T. Structure-activity relationships of a novel class of Entdothelin-A receptor antagonists and discovery of potent and selective receptor antagonists, 2-(Benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2H-chromene-3- carboxylic acid (S-1255). 1. Study on structure-activity relationships and basic structure crucial for ETA antagonism. J. Med. Chem. 2002, 45, 2041-2055.
79. (a) Bauer, H.-U.; Pawelzik, K. R. Qunatifying the neighbourhood preservation of selforganizing feature maps. Computation 1997, 9, 1291-1303.
80. (b) Flexer, A. On the use of self-organizing maps for clustering and visualization. Intell.-Data-Analysis 2001, 5, 373-384.
81. Sauer, W. H. B.; Schwarz, M. K. Molecular shape diversity of combinatorial libraries: A prerequisite for broad bioactivity. J. Chem. Inf. Comput. Sci. 2003, 43, 987-1003.